Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Strauss

Showing results (51-60 of 988) with videos related to

Pageof 99
Sort By:
Transfusion|January 1, 1990
The true rate of donor seropositivity to HIVR G Strauss
Transfusion|August 9, 2016
Optimal prevention of transfusion-transmitted cytomegalovirus (TTCMV) infection by modern leukocyte reduction alone: CMV sero/antibody-negative donors needed only for leukocyte productsRonald G Strauss
Journal of Clinical Apheresis|October 16, 2002
Rationale for medical director acceptance or rejection of allogeneic plateletpheresis donors with underlying medical disordersRonald G Strauss
Transfusion|January 5, 2002
Economy of platelet transfusions from a hospital perspective: pricing predicates practiceR G Strauss
Transfusion|December 9, 2004
Low-dose prophylactic platelet transfusions: time for further study, but too early for routine clinical practiceRonald G Strauss
Journal of Clinical Apheresis|January 1, 1991
Current status of hemapheresis in the United StatesR G Strauss
Transfusion|July 1, 1993
The value of postoperative red cell transfusions is unclearR G Strauss
Hematology/Oncology Clinics of North America|December 1, 1994
Granulocyte transfusion therapyR G Strauss
Blood Reviews|September 7, 2010
Anaemia of prematurity: pathophysiology and treatmentRonald G Strauss
Transfusion|December 11, 2013
Platelet transfusion volume reduction: it can be done, but why do it?Ronald G Strauss
Pageof 99

Showing results (51-60 of 988) with videos related to

Sort By:
Pageof 99
Transfusion|January 1, 1990
The true rate of donor seropositivity to HIVR G Strauss
Transfusion|August 9, 2016
Optimal prevention of transfusion-transmitted cytomegalovirus (TTCMV) infection by modern leukocyte reduction alone: CMV sero/antibody-negative donors needed only for leukocyte productsRonald G Strauss
Journal of Clinical Apheresis|October 16, 2002
Rationale for medical director acceptance or rejection of allogeneic plateletpheresis donors with underlying medical disordersRonald G Strauss
Transfusion|January 5, 2002
Economy of platelet transfusions from a hospital perspective: pricing predicates practiceR G Strauss
Transfusion|December 9, 2004
Low-dose prophylactic platelet transfusions: time for further study, but too early for routine clinical practiceRonald G Strauss
Journal of Clinical Apheresis|January 1, 1991
Current status of hemapheresis in the United StatesR G Strauss
Transfusion|July 1, 1993
The value of postoperative red cell transfusions is unclearR G Strauss
Hematology/Oncology Clinics of North America|December 1, 1994
Granulocyte transfusion therapyR G Strauss
Blood Reviews|September 7, 2010
Anaemia of prematurity: pathophysiology and treatmentRonald G Strauss
Transfusion|December 11, 2013
Platelet transfusion volume reduction: it can be done, but why do it?Ronald G Strauss
Pageof 99